Annexon is a clinical-stage biopharmaceutical company developing a pipeline of therapies for patients with classical complement-mediated disorders of the body, brain and eye. Co.'s pipeline of products is based on its platform technology addressing autoimmune and neurodegenerative disease processes. Co.'s first product candidate, ANX005, is a full-length monoclonal antibody formulated for autoimmune and neurodegenerative disorders. Co.'s second product candidate, ANX007, is an antigen-binding fragment formulated for the treatment of neurodegenerative ophthalmic disorders. Co. is also developing ANX009, a subcutaneous formulation for the treatment of systemic autoimmune diseases. The ANNX stock yearly return is shown above.
The yearly return on the ANNX stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2021 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the ANNX annual return calculation with any dividends reinvested as applicable (on ex-dates).
|